End Stage Renal Disease (ESRD) Drugs Market Analysis & Forecast 2025-2031

Overview

End-stage renal disease has become a major health problem in the last few decades. The number of incidence of chronic kidney disease is growing rapidly particularly in the developing world. The disease affects more than 37 million people in the U.S. alone. The disease is more common in people aged 65 years or older. At a certain level of renal function, progression of chronic kidney disease to end-stage renal disease is inevitable. Patients suffering from end-stage renal disease are associated with other complications such as anemia, blood pressure, elevated phosphorus levels, vitamin D deficiency and many more which requires constant administration of drugs and therapies. The disease has a devastating effect on health, requires proper clinical attention and is associated with huge medical costs.  

Global End-Stage Renal Disease (ESRD) Drugs Market is driven by growing prevalence of kidney related diseases, rising geriatric population, favourable reimbursement policies and growing access to healthcare services in developing countries. In addition to this rising obesity, diabetes, investments in development of new drugs for renal diseases, number of potential drugs in pipeline for clinical trials and FDA approval are expected to drive the global end-stage renal disease market over the forecast period. However, longer clinical trials and stringent regulatory policies are hindering the growth of the market. The developing scientific understanding of End-stage renal disease at the molecular level and rising therapeutic efficacy of drug response are projected to drive the market in the forecast period.  

Drug types & Competitive analysis

Based on drugs type, the End-Stage Renal Disease (ESRD) Drugs Market is segmented into Mk-3866, calcium succinate, sanguinate, pacritinib and others. Depending on the severity of disease these drugs are used to manage complications caused by disease.  Treatment typically involves measures to control signs and symptoms, decrease complications and progression of the disease. The pacritinib segment is projected to experience the fastest growth in the End-Stage Renal Disease (ESRD) Drugs Market during the forecast period. Increasing research initiatives to develop novel drugs for end-stage renal disease treatment is expected to boost the growth of the market.   

Competitive analysis included in research study helps users to understand key players market positioning and marketing strategies. Manufacturers in the End-Stage Renal Disease (ESRD) Drugs Market are focusing on adopting strategies such as product launches and FDA approvals, Research & Development investments, government funding, and partnerships to discover new drugs for the patients worldwide.  New product launches and development of the existing platforms have remained the key strategy of these players. For instance, in March, 2020 FDA granted fast track designation for empagliflozin a drug manufactured by Boehringer Ingelheim and Eli Lilly for treatment of chronic kidney disease.  

In September, 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval for drug INVOKANA (Canagliflozin). The drug reduces the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease. Moreover companies are also engaging in significant acquisitions, mergers, collaborations, and strategic partnerships to lift their growth. For instance in June 2018, Akebia Therapeutics merged with Boston-based Keryx Biopharmaceuticals Company creating a 1billion dollar kidney disease company. The merger will let both companies stand up against larger players in the multi-billion dollar renal market.  

Application & Regional analysis

Application wise End-Stage Renal Disease (ESRD) Drugs Market is categorized into hospitals, clinics and research institutes. Hospitals segment dominated the market in 2023. Treatment for end-stage renal disease usually requires a hospital stay. The increasing cases of end-stage renal disease and the rising number of hospital admissions are the major factors fueling the segment growth. In addition, the growing number of private and government hospitals and effective diagnosis and management of disease are anticipated to positively impact the segment growth over the forecast period.   

Regional outlook of research study is based on analysis of market in North America, Europe, Asia Pacific, Middle East, South America, and Africa & Rest of the World. North America dominated the global end-stage renal disease drugs market in 2023. The growth in the region was attributed to the rising prevalence of end-stage renal disease, sophisticated healthcare facilities and better reimbursement policies for the treatment of end-stage renal disease. The U.S. accounted for the largest revenue share in the North American market due to significant increase in the number of incidences of chronic kidney disease. According to the Centers for Disease Control and Prevention 15 % of US adults i.e. about 37 million projected to have chronic kidney disease.  

Asia Pacific is expected to witness the fastest growth in the forecast period owing to the rising number of chronic kidney diseases due to increasing rates of diabetes and hypertension. The growing prevalence is generating significant demand for pharmaceuticals, dialysis treatments and cutting-edge kidney technologies. Chronic kidney disease is becoming a major health problem in china. The country has 119.5 million chronic kidney disease patients and the number is expected to increase in future. In addition to this growing geriatric population in Japan, China, Korea, India and other countries will offer several growth opportunities for the market in the forecast period. South America and the Middle East are anticipated to show positive growth during the forecast period.  The regions are expected to witness significant growth in coming years due to developing healthcare infrastructure in rapidly growing countries such as Brazil, Mexico and UAE.   

Global End-Stage Renal Disease (ESRD) Drugs Market : Drug Types

• Mk-3866
• Calcium Succinate
• Sanguinate
• Pacritinib
• Others

Global End-Stage Renal Disease (ESRD) Drugs Market : Application

• Hospitals
• Clinics
• Research institutes

Global End-Stage Renal Disease (ESRD) Drugs Market : Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study consists of following key players in Global End-Stage Renal Disease (ESRD) Drugs Market :

• Pfizer
• Baxter
• Johnson& Johnson
• Bayer AG
• Novartis
• Eli Lilly
• AstraZeneca
• Teva Pharmaceutical

Geographical analysis of Global End-Stage Renal Disease (ESRD) Drugs Market :

• North America
  • U.S.A
  • Canada
• Europe
  • France
  • Germany
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South East Asia
• Latin America
  • Brazil
• Middle East and Africa

Global End-Stage Renal Disease (ESRD) Drugs Market Report delivers a comprehensive analysis of the following parameters :

• Market Forecast for 2023-29
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End-user/application Analysis

Global End Stage Renal Disease (ESRD) Drugs Market Report delivers a comprehensive analysis of the following parameters:

• Market Forecast for 2025-2031
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End user/application Analysis

---

Frequently Asked Questions (FAQ)